StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$44.46−1.23 (-2.69%)

Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –

Earnings

Rigel Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$80.90M
+16.4% on a year earlier
EPS, Q3 FY2026
$0.65
$1.46 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Rigel Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$80.90M+16.4%$0.65Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$78.70M-22.6%$0.88Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$58.80M+10.3%$0.44Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026during market hours$69.80M+21.2%$13.54Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours$69.50M+25.7%$1.46Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025during market hours$101.70M+176.4%$3.28Release
Q1 FY2025ended Mar 31, 2025May 6, 2025during market hours$53.30M+80.7%$0.63Release
Q4 FY2024ended Dec 31, 2024Mar 4, 2025during market hours$57.60M+60.9%$0.80Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$55.31M+96.8%$0.70Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$36.80M+36.8%-$0.06Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$29.50M+13.0%-$0.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Rigel Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net product salesFY2026$255.00M – $260.00M$275.00M – $290.00MLoweredNov 5, 2026
total revenuesFY2026$285.00M – $295.00M$275.00M – $290.00MRaisedAug 4, 2026
Contract revenuesFY2026$20.00M – $25.00M–LoweredMay 5, 2026
Contract revenuesFY2026$20.00M – $25.00M–LoweredMar 3, 2026
net product salesFY2026$255.00M – $265.00M–NewMay 5, 2026
Net product salesFY2026$255.00M – $265.00M–NewMar 3, 2026

Guidance vs results

The last range Rigel Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$285.00M – $290.00M$294.30MΣ4QAbove range

Guidance history

Every forecast Rigel Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Net product salesFY2026$255.00M – $260.00MLowered
Nov 5, 2026total revenuesFY2026$290.00M – $295.00MRaised
Nov 5, 2026Contract revenuesFY2026$35.00MLowered
Aug 4, 2026total revenuesFY2026$285.00M – $295.00MRaised
Aug 4, 2026Net product salesFY2026$255.00M – $265.00MLowered
Aug 4, 2026Contract revenuesFY2026$30.00MLowered
May 5, 2026Contract revenuesFY2026$20.00M – $25.00MLowered
May 5, 2026net product salesFY2026$255.00M – $265.00MNew
May 5, 2026Total revenuesFY2026$275.00M – $290.00MRaised
Mar 3, 2026Net product salesFY2026$255.00M – $265.00MNew
Mar 3, 2026Contract revenuesFY2026$20.00M – $25.00MLowered
Mar 3, 2026total revenuesFY2026$275.00M – $290.00MNew
Jan 12, 2026total revenueFY2026$275.00M – $290.00MNew
Jan 12, 2026net product salesFY2026$255.00M – $265.00MLowered
Jan 12, 2026contract revenuesFY2026$20.00M – $25.00MLowered
Nov 4, 2025total revenueFY2025$285.00M – $290.00MNew
Nov 4, 2025Net product salesFY2025$225.00M – $230.00MLowered
Nov 4, 2025Contract revenues from collaborationsFY2025$60.00MLowered
Aug 5, 2025Net product salesFY2025$210.00M – $220.00MRaised
Aug 5, 2025Contract revenues from collaborationsFY2025$60.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Rigel Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Rigel Reports Third Quarter 2026 Financial Results
    Results
  2. Rigel Reports Second Quarter 2026 Financial Results
    Results
  3. Rigel Reports First Quarter 2026 Financial Results
    Results
  4. Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    Results
  5. Rigel Provides Business Update and 2026 Outlook
    Results
  6. Rigel Presents Updated Data from the Ongoing
    News
  7. Rigel Reports Third Quarter 2025 Financial Results
    Results
  8. Rigel Reports Second Quarter 2025 Financial
    Results
  9. Rigel Reports First Quarter 2025 Financial Results
    Results
  10. Rigel Announces Settlement Agreement Resolving
    News
  11. Rigel Reports Fourth Quarter and Full Year 2024
    Results
  12. Rigel Provides Business Update and 2025 Outlook
    Results
  13. Rigel Highlights Initial Data from Ongoing Phase
    News
  14. Rigel Reports Third Quarter 2024 Financial Results
    Results
  15. Reports Second Quarter 2024 Financial
    Results

See a number that looks wrong?